	US 11,717,540 B2
	Modified immune cells and uses thereof
Gerald F. Swiss, San Diego, CA (US)
Assigned to ISI LIFE SCIENCES, INC., Newport Beach, CA (US)
Appl. No. 16/645,727
Filed by ISI LIFE SCIENCES, INC., Newport Beach, CA (US)
PCT Filed Sep. 7, 2018, PCT No. PCT/US2018/050089 § 371(c)(1), (2) Date Mar. 9, 2020, PCT Pub. No. WO2019/051317, PCT Pub. Date Mar. 14, 2019.
Claims priority of provisional application 62/555,445, filed on Sep. 7, 2017.
Claims priority of provisional application 62/585,472, filed on Nov. 13, 2017.
Prior Publication US 2020/0297765 A1, Sep. 24, 2020
Int. Cl. C07D 401/14 (2006.01); A61K 31/192 (2006.01); A61K 31/395 (2006.01); A61K 31/454 (2006.01); A61K 35/17 (2015.01); A61K 47/55 (2017.01); A61K 39/395 (2006.01); C07D 475/04 (2006.01); C07K 16/22 (2006.01); C07K 19/00 (2006.01); C12N 5/078 (2010.01); C07D 257/00 (2006.01)

CPC A61K 35/17 (2013.01) [A61K 39/3955 (2013.01); A61K 47/551 (2017.08); C07D 257/00 (2013.01); C07D 475/04 (2013.01); C07K 16/22 (2013.01); C07K 19/00 (2013.01); C12N 5/0634 (2013.01)]

17 Claims

1. A conjugate having a folic acid or pteroic acid covalently bound to (1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl] methyl]-1,4,8,11-tetrazacyclotetra-decane) optionally through a linker.